July 25, 2019
Researchers recently found that adult patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) experience reduced disease activity and improved health-related quality of life (HRQoL) and productivity when treated with Dupixent (dupilumab; Sanofi and Regeneron). The findings of this study were published online in Allergy.
According to the study team, a previous clinical trial examined the addition of Dupixent to mometasone furoate in patients with CRSwNP refractory to intranasal corticosteroids (INCS). The results of this study showed significantly improved endoscopic, radiographic, and clinical endpoints and patient-reported outcomes.
“The objective of this analysis was to examine the impact of [Dupixent] treatment on HRQoL and productivity using secondary outcome data from this trial,” the authors explained.
For the study, the researchers randomized patients to begin subcutaneous Dupixent or placebo following use of a 4-week mometasone furoate nasal spray.
According to the findings, the rate of patients with moderate-to-severe CRSwNP decreased from 86.2% to 21.4% with Dupixent and 88.0% to 84.2% with placebo following 16 weeks of treatment. Further, patients treated with Dupixent experienced a significantly greater improvement in HRQoL and had a significantly lower adjusted annualized mean number of sick-leave days.
“In adults with CRSwNP refractory to treatment with INCS alone, the addition of dupilumab reduced disease severity, significantly improved HRQoL, and improved productivity,” study authors concluded.
Bachert C, Hellings PW, Mullol J, et al. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis [published online July 15, 2019]. Allergy. doi: 10.1111/all.13984